Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.86 |
| ▸ | ABL2 | P42684 | 6/20 | 0.86 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.60 |
| ▸ | KIT | P10721 | 4/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | BCR | P11274 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19317696 | 0.93 | ABL1 (0.89) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317676 | 0.93 | ABL1 (1.00) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317694 | 0.91 | ABL1 (0.89) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317699 | 0.85 | ABL1 (0.86) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317690 | 0.83 | ABL1 (0.83) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317700 | 0.83 | ABL1 (0.87) | ABL1ABL2MAPK14RET | |
| SCHEMBL19317688 | 0.83 | ABL1 (0.81) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317682 | 0.82 | ABL1 (0.81) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317678 | 0.82 | ABL1 (0.81) | ABL1ABL2MAPK14KITRET | |
| SCHEMBL19317705 | 0.82 | ABL1 (0.87) | ABL1ABL2MAPK14RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | CORNELL UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | CORNELL UNIVERSITY | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170252350-A1 | SMALL MOLECULE IRE1-ALPHA INHIBITORS | XBP1, ERN1, ERN2 | ABL1 3732/4885ABL2 4526/4885MAPK14 1337/4885 |
| US-20220160705-A1 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | PTGES, PTGS1, PTGES2 | ABL1 4516/4885ABL2 2755/4885MAPK14 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.